Results of the ACCEL trial: Dosimetry in accelerated partial breast irradiation.
APBI
Accelerated partial breast irradiation
Class solution
Dosimetry
Journal
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
ISSN: 1879-0887
Titre abrégé: Radiother Oncol
Pays: Ireland
ID NLM: 8407192
Informations de publication
Date de publication:
06 2020
06 2020
Historique:
received:
11
12
2019
revised:
17
02
2020
accepted:
03
03
2020
pubmed:
1
4
2020
medline:
15
4
2021
entrez:
1
4
2020
Statut:
ppublish
Résumé
To report the achieved dosimetry in the ACCEL trial and compare the results to reported dosimetry from the major accelerated partial breast irradiation (APBI) phase III trials. The ACCEL trial was a single arm, phase II, prospective cohort study. A five-field, inverse-planned, IMRT strategy was employed using a class solution technique to increase planning consistency including high dose conformity and low normal tissue dose to the ipsilateral breast. Between 2016 and 2019, 283 patients were treated with 27 Gy in five fractions in consecutive days. The average PTV conformity index was 1.1. For the ipsilateral breast, the median (range) volume receiving 95% and 50% of the prescription dose was 9.7% (3.2-22.4) and 30.3% (11.1-54.6), respectively. Compared to major APBI phase III trial constraints, this reduction in irradiated volume at the 95% and 50% isodose levels represents a reduction of 209 cm The IMRT planning strategy employed in the ACCEL trial demonstrated consistent and superior dosimetry by comparison to conventionally used 3D CRT techniques. Future APBI trials should update dosimetric constraints.
Identifiants
pubmed: 32224317
pii: S0167-8140(20)30112-2
doi: 10.1016/j.radonc.2020.03.004
pii:
doi:
Types de publication
Clinical Trial, Phase III
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
50-55Informations de copyright
Copyright © 2020 Elsevier B.V. All rights reserved.